Skip to search boxSkip to navigationSkip to main content

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

  • Preetesh Jain
    ,
  • Hagop M. Kantarjian
    ,
  • Ahmad Ghorab
    ,
  • Koji Sasaki
    ,
  • Elias J. Jabbour
    ,
  • Graciela Nogueras Gonzalez
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
    ,
  • University of California at Irvine
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>BACKGROUND: Outcomes in patients with chronic myeloid leukemia in blast phase (CML-BP) are historically dismal. Herein, the authors sought to analyze the characteristics, prognostic factors, and survival outcomes in patients with CML-BP in the tyrosine kinase inhibitor (TKI) era. METHODS: A total of 477 patients with CML-BP were treated with a TKI at some point during the course of their CML. Cox proportional hazard models identified characteristics that were predictive of survival. Overall survival and failure-free survival were assessed. Optimal cutoff points for specific parameters were identified using classification and regression tree (CART) analysis. RESULTS: The median age of the patients was 53 years (range, 16-84 years) and 64% were male. Approximately 80% of patients initially were diagnosed in the chronic phase of CML at a median of 41 months (range, 0.7-298 months) before transformation to CML-BP. De novo CML-BP occurred in 71 patients. Approximately 72% of patients received TKI therapy before CML-BP. The initial therapy for CML-BP included a TKI alone (35%), a TKI with chemotherapy (46%), and non-TKI therapies (19%). The median overall survival was 12 months and the median failure-free survival was 5 months. In multivariate analysis, myeloid immunophenotype, prior TKI, age ≥58 years, lactate dehydrogenase level ≥1227 IU/L, platelet count < 102 K/μL, no history of stem cell transplantation, transition to BP from chronic phase/accelerated phase, and the presence of chromosome 15 aberrations predicted for a significantly increased risk of death. Achievement of major hematologic response and/or complete cytogenetic response to first-line treatment was found to be predictive of better survival. The combination of a TKI with intensive chemotherapy followed by stem cell transplantation appeared to confer the best outcome. CONCLUSIONS: Patients with CML-BP continue to pose a therapeutic challenge, have dismal outcomes, and require newer treatment approaches. Cancer 2017;123:4391-402.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 4391-4402 (12 pages)

Journal (Volume, Issue Number)

Cancer (Volume 123, Issue 22)

Publication milestones

  • Published - 11/15/2017

Publication status

Published - 11/15/2017

ISSN

0008-543X

Publication IDs

  • Scopus: 85026356485
  • PubMed: 28743165
  • ORCID: /0000-0002-8636-1071/work/68811259

Publication metrics

Metrics

Fractional count
1
Fractional count
0.05
Fractional count
21
Fractional count
0.95
Fractional count
1
Fractional count
1
SciVal
FWCI
2.81
SciVal
Author count
22
SciVal
citations
49
SciVal
Paper percentile
97
SciVal
Top percentile
5
Scopus
citations

PlumX, opens in new tab

Mentions
2
Captures
170
Citation count
152

Funding Details

FunderFunding number
NCI
P01CA049639